Emmaus Life Sciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for rare and orphan diseases, particularly sickle cell disease (SCD). The company's flagship product, Endari®, is a prescription-grade L-glutamine oral powder approved by the FDA for the treatment of SCD in patients aged five years and older. Endari® is designed to reduce the acute complications associated with sickle cell disease, which affects approximately 100,000 individuals in the United States. The product is well-tolerated and can be easily consumed with liquids, making it a convenient option for patients. Emmaus is also exploring the use of Endari® for other conditions, such as diverticulosis, indicating a broader commitment to addressing various health challenges.

In addition to its product offerings, Emmaus Life Sciences has embraced telehealth solutions to enhance patient access to Endari®. Through a partnership with UpScript, the company provides a platform that allows patients to consult with healthcare providers remotely, facilitating same-day prescriptions and home delivery of medications. This initiative aims to improve the overall patient experience and ensure that individuals with sickle cell disease can receive timely treatment while minimizing the risks associated with in-person visits. Emmaus continues to expand its market presence and is actively engaged in research and development to further its mission of improving patient outcomes through innovative therapies.

United States

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease.  We are initially focusing our product development efforts in Sickle Cell Disease, a genetic disorder.  Our lead product candidate is an oral pharmaceutical grade L-glutamine treatment that demonstrated positive clinical results in our completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.

Emmaus Life Sciences

Company Details